Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... the most promising biotech start-up company at the recent ... a proprietary process to convert wastewater from food and ... was given top honors out of 22 total entries ... from the sponsoring Colorado law firm of Dorsey & ...
... 8 Prosolia, Inc. introduces a new,advanced Omni Spray Ion ... Omni Spray 2-D Ion Source has an automated,surface platform which ... up to 76 mm by 114 mm, which is the ... The Omni Spray 2-D Ion Source ...
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
Cached Biology Technology:Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 2Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 3Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 4Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 5Prosolia to Introduce Omni Spray(R) Ion Source in 2-D Format 2Adecco Receives Honor From Alcon Laboratories 2
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Xanex or Xanax? Or maybe Zantac? If you're a health ... , An estimated 1.3 million people in the United States ... U.S. Federal Drug Administration (FDA) has been working to reduce ... in which a patient needed an injection of Narcan but ...
... Genes & Development, Dr. Mary Ellen Perry and colleagues ... for cancer therapies. , The p53 tumor suppressor plays ... strategies aim to activate p53 in order to curb ... and therefore an attractive target to modulate p53 activity ...
... death by suicide generally decreases in the weeks after ... study led by Group Health Cooperative researchers and published ... Psychiatry. The study also found that the risk of ... less than the risk posed by older medications. ...
Cached Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
Biology Products: